Dixon Mitchell Investment Counsel Inc. Raises Position in Certara, Inc. $CERT

Dixon Mitchell Investment Counsel Inc. raised its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 78.5% during the 4th quarter, HoldingsChannel reports. The fund owned 1,546,299 shares of the company’s stock after acquiring an additional 679,919 shares during the quarter. Dixon Mitchell Investment Counsel Inc.’s holdings in Certara were worth $13,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. increased its holdings in Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after acquiring an additional 2,870 shares during the last quarter. Osaic Holdings Inc. boosted its position in Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Certara by 499.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of Certara in the 2nd quarter worth approximately $83,000. Finally, Curated Wealth Partners LLC purchased a new stake in Certara during the fourth quarter valued at approximately $89,000. 73.96% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

CERT has been the topic of a number of research reports. Craig Hallum cut their price objective on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. Morgan Stanley dropped their target price on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. BMO Capital Markets decreased their price target on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Tuesday, May 12th. Stephens decreased their price target on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Finally, Robert W. Baird decreased their price target on shares of Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $8.85.

Certara Price Performance

Certara stock opened at $5.20 on Friday. Certara, Inc. has a 12-month low of $4.45 and a 12-month high of $13.88. The stock has a market cap of $808.96 million, a P/E ratio of -52.00 and a beta of 1.49. The company has a 50-day moving average price of $5.58 and a 200 day moving average price of $7.19. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The company had revenue of $106.92 million for the quarter, compared to analyst estimates of $106.13 million. During the same quarter in the prior year, the business earned $0.14 earnings per share. Certara’s revenue was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Sell-side analysts anticipate that Certara, Inc. will post 0.24 earnings per share for the current year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.